Material Insights · Understanding the Material World

Vitamins: Emissions

Solvents, chromium waste and long energy-hungry syntheses

What this tab covers The greenhouse-gas footprint per tonne, split by lifecycle phase (feedstock, production, movement, use, end of life), the global total, other environmental impacts, levers and low-carbon routes, India's position, and where the investment opportunity lies.

Per kg of vitamin, cradle-to-gate. Intensity: not published. Global total: not published.

Footprint by lifecycle phase

PhaseIntensityShareMain sources of emissionsNotesSource
Feedstocknot published–petrochemical intermediates; maize glucose for fermented vitaminsindicative
Production / processnot published–many reaction and purification steps, solvents, steam; coal-based energy in Chinaindicative
Movementsmall–container shippingindicative
Usenot applicable–consumed by animals and peoplenot applicable
End of lifenot applicable–metabolisednot applicable

Other environmental impacts

Solvent and chromium wastes (vitamin K3), process safety incidents, wastewater from fermentation.

Levers to cut emissions

  • Fermentation routes to replace synthesis (e.g. fermented vitamin B2 replaced chemical routes; indicative)
  • Renewable energy at Chinese chemical parks
  • Solvent recovery and green chemistry in A and E syntheses

India

India's vitamin footprint sits mostly in imports; its B12 and folic acid plants are part of its pharma base (indicative).

Emission figures are indicative global averages from the life-cycle studies named; actual footprints vary widely by site, energy mix and method.

Low-carbon routes

RouteIntensityCost premiumStatusSource
Precision fermentation of vitamins A and E precursorsnot publishednot publishedresearch and pilot (indicative)indicative
For a climate investor Vitamins matter to a climate fund mainly as a supply-security and nutrition story, not a large emissions source. The investable angle in India is domestic production of imported vitamins (A, E, D3, C) and fermentation-based routes, supported by bulk-drug incentives. What has to be true: cost parity with Chinese integrated producers, which currently earn high margins (NHU's net margin about 30% in 2025, derived).